News | Peripheral Artery Disease (PAD) | June 26, 2017

Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty System

Company also announced enrollment of first patient in DISRUPT PAD III global clinical trial

Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty System

June 26, 2017 — Shockwave Medical recently announced two milestones for its Lithoplasty System for the treatment of calcified plaque in patients with peripheral artery disease (PAD). The first patient was enrolled in the global DISRUPT PAD III clinical trial at the Medical University of Graz, Austria, and the first patient was treated in a commercial case in the United States, at Pottstown Memorial Medical Center in Pottstown, Pa.

The Lithoplasty System is designed to treat calcified leg artery blockages with lithotripsy, sonic pressure waves historically used to treat patients with kidney stones. The technology is now commercially available in both the United States and Europe for the treatment of calcified plaque in peripheral arteries.

Watch the VIDEO "Breaking Up Calcified Lesions Without Vessel Trauma."

DISRUPT PAD III is the largest ever multi-center randomized trial to exclusively enroll patients with heavily calcified PAD. The objective of the post-market trial is to assess the optimal therapy to dilate heavily calcified lesions by comparing the Shockwave Medical Lithoplasty System versus traditional angioplasty, with a primary goal of achieving less than 30 percent residual stenosis without the need for stenting. In addition, all patients who do not receive a stent will be treated with a drug-coated balloon. The trial will enroll 334 patients in up to 45 global sites.

Marianne Brodmann, M.D., of the Medical University of Graz, Austria, enrolled the first patient in the trial.

“I’m pleased to be taking part in this important study of the Lithoplasty System for the treatment of complex peripheral artery disease,” said Brodmann. “Patients with challenging heavily calcified PAD have been excluded from previous drug coated balloon trials. The results of the DISRUPT PAD III randomized trial will bear important implications for treatment of this very important patient population.”

Edward Pavillard, D.O., a vascular surgeon with Pottstown Memorial Medical Center, used the Lithoplasty System to treat a patient with PAD in the first commercial U.S. case.

“Peripheral artery disease is a common, painful and possibly limb-threatening disease that can be challenging to treat,” Pavillard said. “Calcified plaque has long been an Achilles heel for many endovascular interventions. The Lithoplasty System is a significant advancement in the treatment of PAD, as it provides a new treatment option with potentially less risk of damage or injury to the vessel. I am excited to be among the first in the United States to use this technology to help restore blood flow and improve the quality of life for my patients with complex, traditionally difficult to treat peripheral lesions.”

Watch the VIDEO How a Lithoplasty Balloon Shatters Calcified Plaque in Arteries With Ultrasound

Read the article FDA Clears Lithoplasty Balloon That Shatters Calcified Lesions With Ultrasound

Read the article First U.S. Patient Treated in DISRUPT PAD III Study of Lithoplasty Technology

 

For more information: www.shockwavemedical.com

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init